Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it has been accepted to list its common shares on the Frankfurt Stock Exchange (FSE) under the trading symbol (5NP). The Company’s shares are now cross-listed on the Canadian Securities Exchange (CSE) and the FSE.
“We have been exceptionally fortunate to have received investment inquiries internationally in such a small period of time,” says Tim Moore, Co-CEO of Havn Life. “Our team has been moving quickly to make Havn Life’s common shares available to European investors. The team will continue to work towards making our shares available to investors globally.”
On Behalf of The Board of Directors
Susan Chapelle & Tim Moore